Myofascial Pain: An Open Study on the Pharmacotherapeutic Response to Stepped Treatment with Tricyclic Antidepressants and Gabapentin

Aims: To evaluate, in an open trial, the pharmacotherapeutic efficacy of tricyclic antidepressant (TCA) drugs and gabapentin in patients with persistent myofascial pain and to identify patient and pain characteristics that may predict treatment outcome. Methods: A stepped pharmacotherapeutic protocol was employed. All 42 patients having persistent facial pain with tenderness of regional muscles were first prescribed amitriptyline, but those with side effects were subsequently transferred to nortriptyline. In patients where no response to TCAs was observed, gabapentin was initiated. Outcome was assessed by employing prospective diaries recording pain intensity measured with an 11-point (0–10) verbal pain scale (VPS). Individual characteristics in these patients and their influence on drug response and outcome were analyzed; specifically, patients treated with TCAs were compared with those subsequently treated with gabapentin. Chi-square and t tests were used to analyze the data. Results: A total of 23 patients responded to TCAs and continued on this regimen, while 19 were resistant to TCAs and were subsequently treated with gabapentin. Their mean (± SD) VPS score at baseline was 6.5 ± 1.9 on an 11-point scale. In TCA-treated patients, 43% showed ≥ 50% reduction in pain intensity. This was achieved with a mean amitriptyline dose of 16 ± 1.1 mg/d and a mean nortriptyline dose of 25 ± 2.1 mg/d. Patients who did not respond to TCAs were characterized by a significantly higher age, more comorbid medical illness, and evidence of more regional pain spread (P < .05). In spite of not responding to TCAs, 36.8% of this group showed ≥ 50% reduction in pain intensity following gabapentin therapy at a mean daily dose of 973.7 ± 68.8 mg. Overall, a stepped approach employing TCAs and gabapentin resulted in 54.8% of all treated patients reporting improvements of ≥ 50% in VPS scores. Conclusion: This study has demonstrated the good pharmacotherapeutic response of persistent myofascial pain, even in more severe cases. Not being a randomized controlled trial, the results may be biased and should be interpreted with caution. Patients who do not respond to TCAs may be a distinct subgroup and this needs further investigation. The results also suggest that gabapentin, at a lower dose than previously reported, is a good alternative in TCA-resistant patients.

amitriptyline; antiepileptic drug; myalgia; nortriptyline; orofacial pain

1. Tjakkes GH, Reinders JJ, Tenvergert EM, Stegenga B. TMD pain: The effect on health related quality of life and the influence of pain duration. Health Qual Life Outcomes 2010;8:46.

2. Maixner W, Diatchenko L, Dubner R, et al. Orofacial pain prospective evaluation and risk assessment study—the OPPERA study. J Pain 2011;12:T4–T11.

3. Kino K, Sugisaki M, Haketa T, et al. The comparison between pains, difficulties in function, and associating factors of patients in subtypes of temporomandibular disorders. J Oral Rehabil 2005; 32:315–325.

4. Benoliel R, Eliav E, Sharav Y. Classification of chronic orofacial pain: Applicability of chronic headache criteria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:729–737.

5. Benoliel R, Svensson P, Heir GM, et al. Persistent orofacial muscle pain. Oral Dis 2011;17(Suppl 1):23–41.

6. Sherman JJ, Turk DC. Nonpharmacologic approaches to the management of myofascial temporomandibular disorders. Curr Pain Headache Rep 2001;5:421–431.

7. Benoliel R, Sharav Y. Masticatory myofascial pain, and tension-type and chronic daily headache. In: Sharav Y, Benoliel R (eds). Orofacial Pain and Headache. St Louis: Mosby Elsevier, 2008.

8. Plesh O, Curtis D, Levine J, McCall WD Jr. Amitriptyline treat-ment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil 2000;27:834–841.

9. Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain 1987; 31:199–209.

10. Bendtsen L, Jensen R. Amitriptyline reduces myofascial ten-derness in patients with chronic tension-type headache. Cephalalgia 2000;20:603–610.

11. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250–1256.

12. Haviv Y, Zadik Y, Sharav Y, Benoliel R. Painful traumatic trigeminal neuropathy: An open study on the pharmacotherapeutic response to stepped treatment. J Oral Facial Pain Headache 2014;28:52–60.

13. Kimos P, Biggs C, Mah J, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: A randomized controlled trial. Pain 2007;127:151–160.

14. Chandra K, Shafiq N, Pandhi P, Gupta S, Malhotra S. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: A randomized, double-blind clinical trial—the GONIP Trial. Int J Clin Pharmacol Ther 2006;44:358–363.

15. Benoliel R, Eliav E, Sharav Y. Self-reports of pain-related awakenings in persistent orofacial pain patients. J Orofac Pain 2009;23:330–338.

16. Sharav Y, Leviner E, Tzukert A, McGrath PA. The spatial distribution, intensity and unpleasantness of acute dental pain. Pain 1984;20:363–370.

17. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–172.

18. Benoliel R, Birman N, Eliav E, Sharav Y. The International Classification of Headache Disorders: Accurate diagnosis of orofcial pain? Cephalalgia 2008;28:752–762.

19. Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Oral Facial Pain Headache 2014;28:6–27.

20. Fumal A, Schoenen J. Chronic tension-type headache. In: Goadsby PJ, Silberstein SD, Dodick D (eds). Chronic Daily Headache. Hamilton, Ontario: BC Decker, 2005:57–64.

21. Jensen R, Rasmussen BK, Pedersen B, Olesen J. Muscle tenderness and pressure pain thresholds in headache. A popula-tion study. Pain 1993;52:193–199.

22. Langemark M, Olesen J, Poulsen DL, Bech P. Clinical characterization of patients with chronic tension headache. Headache 1988;28:590–596.

23. Benoliel R, Sharav Y. Tender muscles and masticatory myofascial pain diagnosis: How many or how much? J Orofac Pain 2009;23:300–301.

24. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6: 301–355.

25. van Grootel RJ, van der Glas HW, Buchner R, de Leeuw JR, Passchier J. Patterns of pain variation related to myogenous temporomandibular disorders. Clin J Pain 2005;21:154–165.

26. Benoliel R, Eliav E, Elishoov H, Sharav Y. Diagnosis and treatment of persistent pain after trauma to the head and neck. J Oral Maxillofac Surg 1994;52:1138–1147; discussion 1147–1148.

27. Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005;25: 1048–1053.

28. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234–241.

29. Magnusson T, Egermark I, Carlsson GE. A longitudinal epidemiologic study of signs and symptoms of temporomandibulardisorders from 15 to 35 years of age. J Orofac Pain 2000;14: 310–319.

30. Rammelsberg P, LeResche L, Dworkin S, Mancl L. Longitudinal outcome of temporomandibular disorders: A 5-year epidemiologic study of muscle disorders defined by research diagnostic criteria for temporomandibular disorders. J Orofac Pain 2003;17:9–20.

31. Aaron LA, Burke MM, Buchwald D. Overlapping condi-tions among patients with chronic fatigue syndrome, fibro-myalgia, and temporomandibular disorder. Arch Intern Med 2000;160:221–227.

32. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005;94:1131–1139.

33. Gottrup H, Juhl G, Kristensen AD, et al. Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 2004;101:1400–1408.

34. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000;101:359–371.

35. Tuchman M, Barrett JA, Donevan S, Hedberg TG, Taylor CP. Central sensitization and Ca(V)alpha(2)delta ligands in chronic pain syndromes: Pathologic processes and pharmacologic effect. J Pain 2010;11:1241–1249.